FFG will grant 1.19 m EUR in the first year and an additional funding up to 70% of the total budget of 12.5 m EUR will be made over a span of three years.
Arsanis co-founder and chief scientific officer Eszter Nagy said the company is set to establish a wide range of anti-infective antibodies, many of which target nosocomial bacterial infections.
"The FFG grant will support discovery activities of several antibody projects and the pre-clinical and early clinical development of one lead program," Nagy added.